Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:ATHA NASDAQ:IMUX NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.51+0.8%$2.61$0.99▼$3.60$179.85M0.32316,977 shs396,206 shsATHAAthira Pharma$10.33+2.6%$9.57$0.23▼$8.36$40.74M2.79602,475 shs22,984 shsIMUXImmunic$13.05+6.1%$11.37$5.06▼$15.10$167.54M1.2288,888 shs326,555 shsPRQRProQR Therapeutics$1.56+8.3%$1.66$1.33▼$3.10$151.72M0.08704,287 shs551,640 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.80%+10.09%-10.68%-2.33%+141.35%ATHAAthira Pharma+4.68%-8.45%+9.22%+81.12%+275.05%IMUXImmunic+6.10%+8.03%+45.00%+38.83%+41.85%PRQRProQR Therapeutics+8.33%-1.89%-10.86%+8.33%-9.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.51+0.8%$2.61$0.99▼$3.60$179.85M0.32316,977 shs396,206 shsATHAAthira Pharma$10.33+2.6%$9.57$0.23▼$8.36$40.74M2.79602,475 shs22,984 shsIMUXImmunic$13.05+6.1%$11.37$5.06▼$15.10$167.54M1.2288,888 shs326,555 shsPRQRProQR Therapeutics$1.56+8.3%$1.66$1.33▼$3.10$151.72M0.08704,287 shs551,640 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.80%+10.09%-10.68%-2.33%+141.35%ATHAAthira Pharma+4.68%-8.45%+9.22%+81.12%+275.05%IMUXImmunic+6.10%+8.03%+45.00%+38.83%+41.85%PRQRProQR Therapeutics+8.33%-1.89%-10.86%+8.33%-9.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.50Moderate Buy$6.67165.60% UpsideATHAAthira Pharma 1.00Sell$4.00-61.28% DownsideIMUXImmunic 3.00Buy$47.57264.53% UpsidePRQRProQR Therapeutics 2.63Moderate Buy$7.25364.74% UpsideCurrent Analyst Ratings BreakdownLatest ATHA, PRQR, IMUX, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026IMUXImmunic Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/22/2026IMUXImmunic B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $27.005/14/2026IMUXImmunic Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/4/2026IMUXImmunic Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026IMUXImmunic HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00 ➝ $22.004/21/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026IMUXImmunic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$25.004/15/2026IMUXImmunic D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/9/2026PRQRProQR Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.004/8/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.21 per shareN/AATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/AIMUXImmunicN/AN/AN/AN/A$11.10 per shareN/APRQRProQR Therapeutics$17.99M9.14N/AN/A$0.42 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)ATHAAthira Pharma-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%N/AIMUXImmunic-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%8/6/2026 (Estimated)PRQRProQR Therapeutics-$47.73M-$0.50N/AN/AN/A-331.33%-84.87%-37.78%8/6/2026 (Estimated)Latest ATHA, PRQR, IMUX, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026IMUXImmunic-$0.71-$1.08-$0.37-$1.08N/AN/A5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A5/12/2026Q1 2026PRQRProQR Therapeutics-$0.15-$0.15N/A-$0.15$5.19 million$2.35 million3/26/2026Q4 2025ABOSAcumen Pharmaceuticals-$0.50-$0.41+$0.09-$0.41N/AN/A3/12/2026Q4 2025PRQRProQR Therapeutics-$0.08-$0.09-$0.01-$0.09$6.12 million$5.53 million2/26/2026Q4 2025IMUXImmunic-$1.0222-$1.20-$0.1778-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.55ATHAAthira PharmaN/A9.709.70IMUXImmunicN/A4.924.92PRQRProQR TherapeuticsN/A2.482.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ATHAAthira Pharma57.12%IMUXImmunic51.82%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%ATHAAthira Pharma19.80%IMUXImmunic14.00%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million65.51 millionOptionableATHAAthira Pharma403.94 million3.16 millionNo DataIMUXImmunic7013.62 million11.72 millionOptionablePRQRProQR Therapeutics180105.36 million96.51 millionOptionableATHA, PRQR, IMUX, and ABOS HeadlinesRecent News About These CompaniesProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 21 at 2:15 AM | americanbankingnews.comProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash PositionMay 17, 2026 | theglobeandmail.comWall Street Zen Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Strong SellMay 16, 2026 | americanbankingnews.comProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%May 14, 2026 | finance.yahoo.comProQR Announces First Quarter 2026 Operating and Financial ResultsMay 12, 2026 | globenewswire.comProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformMay 11, 2026 | globenewswire.comEarnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineMay 7, 2026 | zacks.comProQR Therapeutics (PRQR) to Release Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4, 2026 | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in AprilApril 29, 2026 | marketbeat.comProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 26, 2026 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving Average - Should You Sell?April 25, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)April 10, 2026 | theglobeandmail.comProQR Therapeutics: Waiting On Proof As AX-0810 Data ApproachesApril 10, 2026 | seekingalpha.comProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventApril 8, 2026 | globenewswire.comProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardApril 8, 2026 | globenewswire.comGrowing optimism about ProQR Therapeutics (PRQR)’s RNA editing platform and future clinical catalystsMarch 26, 2026 | msn.comGrowing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical CatalystsMarch 25, 2026 | insidermonkey.comProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026March 25, 2026 | globenewswire.comProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 18, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBerkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming DueBy Bridget Bennett | May 9, 20263 Crucial Aerospace Component Makers That Analysts LoveBy Nathan Reiff | May 16, 2026Domino's Pizza: Outlook for the Berkshire Holding After Q1 DropBy Leo Miller | April 29, 2026How Berkshire’s New York Times Bet Looks TodayBy Leo Miller | May 14, 2026ATHA, PRQR, IMUX, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.51 +0.02 (+0.80%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.50 0.00 (-0.20%) As of 05/22/2026 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Athira Pharma NASDAQ:ATHA$10.33 +0.26 (+2.58%) As of 05/22/2026Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Immunic NASDAQ:IMUX$13.05 +0.75 (+6.10%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.64 -0.41 (-3.16%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.ProQR Therapeutics NASDAQ:PRQR$1.56 +0.12 (+8.33%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.54 -0.02 (-1.22%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
